Retrospective study of surgery versus non‐surgical management in limited‐disease small cell lung cancer

Thoracic Cancer

Jie Zhang¹  Shaolei Li¹  Xiaoling Chen¹  Jindi Han¹  Jun Nie¹  Ling Dai¹  Weiheng Hu¹  Guangming Tian¹  Xiangjuan Ma¹  Sen Han¹  Di Wu¹  Qingfeng Zheng¹  Yue Yang¹ 

[1] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Oncology II and Thoracic Surgery II, Peking University Cancer Hospital & Institute, Beijing, China

关键词: Limited disease;    small cell lung cancer;    surgery;   

DOI  :  10.1111/1759-7714.12109

来源: Wiley

【 摘 要 】

Abstract

Background

The role of surgery in limited small cell lung cancer (SCLC) is still controversial. To assess the role of surgery in SCLC we performed a retrospective analysis of survival in a group of limited stage patients, who were managed with trimodal therapy including surgery, or with chemotherapy and radiotherapy.

Methods

We performed a retrospective survival analysis in a series of 153 limited stage SCLC patients treated between 1995 and 2013. Kaplan-Meier survival analysis and Cox regression analysis were used to calculate the overall survival of the surgical and non-surgical groups.

Results

Median survival in all patients was 21.5 months. Median survival for surgical and non-surgical patients was 30.5 months and 16.9 months, respectively. The survival curves for the two arms are significantly different (P < 0.01). In multivariate analysis, the benefit of surgical treatment and thoracic radiotherapy varied in a time-dependent fashion.

Conclusions

Our results suggest that surgery added to chemotherapy and radiotherapy may be associated with a therapeutic benefit in limited SCLC.

【 授权许可】

Unknown   
© 2014 Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd